A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00474188 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: CC-5013 (lenalidomide)
DRUG: dexamethasone

Sponsor

Celgene Corporation